Patents by Inventor Tetsuji Yamaoka
Tetsuji Yamaoka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11253626Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.Type: GrantFiled: January 30, 2018Date of Patent: February 22, 2022Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JMS CO., LTD.Inventors: Tetsuji Yamaoka, Maria Chiara Munisso, Atsushi Mahara, Takashi Yamamoto
-
Publication number: 20190365944Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.Type: ApplicationFiled: January 30, 2018Publication date: December 5, 2019Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JMS CO., LTD.Inventors: Tetsuji YAMAOKA, Maria MUNISSO, Atsushi MAHARA, Takashi YAMAMOTO
-
Patent number: 10351600Abstract: A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.Type: GrantFiled: July 28, 2017Date of Patent: July 16, 2019Assignees: National Cerebral and Cardiovascular Center, JMS Co., Ltd.Inventors: Tetsuji Yamaoka, Sachiro Kakinoki, Shunsuke Baba, Yoshiya Hashimoto
-
Publication number: 20170327539Abstract: A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.Type: ApplicationFiled: July 28, 2017Publication date: November 16, 2017Inventors: Tetsuji YAMAOKA, Sachiro KAKINOKI, Shunsuke BABA, Yoshiya HASHIMOTO
-
Patent number: 9642695Abstract: In order to provide an artificial blood vessel that can prevent formation of a thrombus and a method for producing the artificial blood vessel, an artificial blood vessel is used (i) in which a peptide including a specific amino acid sequence has been added to an extracellular matrix obtained from a bio-derived vascular tissue and (ii) whose lumen has a cross sectional diameter of 4 mm or less.Type: GrantFiled: September 5, 2013Date of Patent: May 9, 2017Assignee: JMS CO., LTD.Inventors: Tetsuji Yamaoka, Atsushi Mahara
-
Publication number: 20160137694Abstract: Provided are a peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.Type: ApplicationFiled: April 25, 2014Publication date: May 19, 2016Inventors: Tetsuji YAMAOKA, Sachiro KAKINOKI, Shunsuke BABA, Yoshiya HASHIMOTO
-
Publication number: 20150272719Abstract: In order to provide an artificial blood vessel that can prevent formation of a thrombus and a method for producing the artificial blood vessel, an artificial blood vessel is used (i) in which a peptide including a specific amino acid sequence has been added to an extracellular matrix obtained from a bio-derived vascular tissue and (ii) whose lumen has a cross sectional diameter of 4 mm or less.Type: ApplicationFiled: September 5, 2013Publication date: October 1, 2015Inventors: Tetsuji Yamaoka, Atsushi Mahara
-
Patent number: 9127280Abstract: An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4?-position and 2?-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.Type: GrantFiled: August 31, 2011Date of Patent: September 8, 2015Assignees: Osaka University, National Cerebral and Cardiovascular Center, Tokyo University of Science Education Foundation Administrative OrganizationInventors: Satoshi Obika, Takeshi Imanishi, Tsuyoshi Yamamoto, Keisuke Narukawa, Mariko Shiba, Tetsuji Yamaoka, Hidetaka Torigoe, Atsushi Yamashita, Yoichi Tachibana, Sachiro Kakinoki, Kiyomi Sasaki
-
Patent number: 8871242Abstract: A blood anticoagulant material is provided which has high expandability, reduced influence on living bodies, and can efficiently prevent blood coagulation. A multiblock copolymer having at least a structural unit represented by Formula (1), a structural unit represented by Formula (2), and a structural unit represented by Formula (3) is used: wherein, R1, R2, and R3 in Formulas (1) to (3) each independently represent a divalent organic group, and m and n each independently represent an integer of 2 to 5000.Type: GrantFiled: November 16, 2007Date of Patent: October 28, 2014Assignee: National Cerebral and Cardiovascular CenterInventors: Tetsuji Yamaoka, Satoshi Kato, Atsushi Kasai, Sachiro Kakinoki
-
Patent number: 8834887Abstract: To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.Type: GrantFiled: September 25, 2008Date of Patent: September 16, 2014Assignees: National Cerebral and Cardiovascular Center, Kowa Co., Ltd.Inventors: Tetsuji Yamaoka, Mariko Shiba, Atsushi Mahara, Yoshihito Kato
-
Publication number: 20130172402Abstract: An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4?-position and 2?-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.Type: ApplicationFiled: August 31, 2011Publication date: July 4, 2013Applicants: Osaka University, Tokyo University of Science Educational Foundation Administrative Organization, National Cerebral and Cardiovascular CenterInventors: Satoshi Obika, Takeshi Imanishi, Tsuyoshi Yamamoto, Keisuke Narukawa, Mariko Shiba, Tetsuji Yamaoka, Hidetaka Torigoe, Atsushi Yamashita, Yoichi Tachibana, Sachiro Kakinoki, Kiyomi Sasaki
-
Publication number: 20100209441Abstract: To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.Type: ApplicationFiled: September 25, 2008Publication date: August 19, 2010Applicants: JAPAN AS REP. BY THE PRES. OF NAT'L. CARDIO CENTR, KOWA CO., LTD.Inventors: Tetsuji Yamaoka, Mariko Shiba, Atsushi Mahara, Yoshihito Kato
-
Publication number: 20100030325Abstract: A blood anticoagulant material is provided which has high expandability, reduced influence on living bodies, and can efficiently prevent blood coagulation. A multiblock copolymer having at least a structural unit represented by Formula (1), a structural unit represented by Formula (2), and a structural unit represented by Formula (3) is used: wherein, R1, R2, and R3 in Formulas (1) to (3) each independently represent a divalent organic group, and m and n each independently represent an integer of 2 to 5000.Type: ApplicationFiled: November 16, 2007Publication date: February 4, 2010Applicants: Japan as Rep. by Pres. of Nat. Cardiovascular Ctr., MITSUBISHI CHEMICAL CORPORATIONInventors: Tetsuji Yamaoka, Satoshi Kato, Atsushi Kasai, Sachiro Kakinoki
-
Patent number: 7550512Abstract: The present invention provides a polyethylene glycol derivative having sugar residue-containing side chains and carboxyl group-containing side chains, and a method of preparing the same. The present invention also provides a carrier for drug delivery systems and a carrier for gene transfer, both comprising the polyethylene glycol derivative.Type: GrantFiled: June 3, 2004Date of Patent: June 23, 2009Assignees: Keio University, NOF CorporationInventors: Toshinori Sato, Yoshiyuki Koyama, Tetsuji Yamaoka
-
Publication number: 20070059828Abstract: A carrier for nucleic acid molecule delivery formed from a saccharified copolymer comprising repeating unit (A) having a cationic group, saccharified repeating unit (B). There is further provided a carrier for nucleic acid molecule delivery formed from a saccharified copolymer comprising, in addition to the repeating units (A) and (B), repeating unit (C) having a hydrophobic substituent.Type: ApplicationFiled: November 5, 2004Publication date: March 15, 2007Inventors: Tetsuji Yamaoka, Yutaka Tokiwa, Masaru Kitagawa
-
Publication number: 20050036973Abstract: The present invention provides a polyethylene glycol derivative having sugar residue-containing side chains and carboxyl group-containing side chains, and a method of preparing the same. The present invention also provides a carrier for drug delivery systems and a carrier for gene transfer, both comprising the polyethylene glycol derivative.Type: ApplicationFiled: June 3, 2004Publication date: February 17, 2005Applicants: KEIO UNIVERSITY, NOF CORPORATIONInventors: Toshinori Sato, Yoshiyuki Koyama, Tetsuji Yamaoka
-
Publication number: 20040097659Abstract: The present invention provides a polyethylene glycol derivative having sugar residue-containing side chains and carboxyl group-containing side chains, and a method of preparing the same. The present invention also provides a carrier for drug delivery systems and a carrier for gene transfer, both comprising the polyethylene glycol derivative.Type: ApplicationFiled: August 27, 2003Publication date: May 20, 2004Inventors: Toshinori Sato, Yoshiyuki Koyama, Tetsuji Yamaoka